New to The Street TV’s show line-up, it features six (6) interviews of the following corporations and their representatives:
1). Tonix Pharmaceuticals, Inc.’s (TNXP) interview with Dr. Seth Lederman, MD, and CEO.
2). Sekur Private Data, Ltd.’s (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) interview with Mr. Alain Ghiai, CEO.
4). PetVivo Holdings, Inc.’s (NASDAQ: PETV) (NASDAQ: PETVW) interview with Mr. Mark Middleton, National Sales Director.
6). Linqto’s interviews with Mr. Joe Endoso, Chief Operating Officer (COO), and Ms. Susan Miller, Chief Growth Officer (CGO).
CEO, Dr. Seth Lederman, MD at Tonix Pharmaceuticals, Inc. (TNXP), is back in studio at the Nasdaq Marketplace speaking with New to The Street’s TV Host Jane King. Recently, TNXP released data during three oral presentations at the 2022 American Transplant Congress held at the Center of Transplantation Sciences, Massachusetts General Hospital. TNX-1500 sees exciting results as a therapy in eliminating transplant rejections in the heart and kidneys. Through a collaboration with Massachusetts General Hospital, part of the Harvard Medical School, the TNX-1500 shows data for possible product development for therapeutic prevention of organ transplant rejection. TNX-1500 shows exciting results to date. A particular molecule, CD40-ligand (CD40L) appears to be the reason for transplant rejections. TNXP engineered a monotherapy to block toxicities associated with CD40L; its TNX-1500 in animal studies shows activities to prevent rejections. Dr. Lederman talks about the monkeypox virus and compares the West African and Central African variants. The West African is the one the press reports about, with infections worldwide not appearing deadly. The Central African variant, with no reported cases, can be lethal. TNXP has two patented vaccines, one for smallpox and the other for monkeypox. TNX-801 is a horsepox-based live virus vaccine currently in development to protect against monkeypox and smallpox. The monkeypox vaccine is in-testing with lab monkeys; so far, results look promising in possible prevention. The Company’s fibromyalgia and Long-COVID studies and clinical trials continue at TNXP. Exciting times for the Company for their novel therapies and treatments; Dr. Lederman will come back on a future show with further updates. The on-screen QR code is available during the show; download or visit Tonix Pharmaceuticals, Inc. – https://www.tonixpharma.com/.
A re-airing on this week’s show is the in-studio interview at the Nasdaq Marketplace with Mr. Alain Ghiai, CEO at Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0). Alain talks with TV Host Jane King about the Company’s newest encrypted product, “Chat-by-Invite.” This new text message tool, available in the USA, Canada, Australia, New Zealand, Switzerland, and most of Latin America and Europe, gives subscribers an utterly private chat. It works when the Sekur subscriber sends a text message to a recipient, and a link appears that opens into a private, secure platform hosted in Switzerland. Essentially, the chat occurs on the Swiss servers owned and controlled by Sekur Private Data, Ltd. Once the text message session completes, the text disappears. Hackers won’t know about the transmission because of the highly encrypted military technology operating the product. There is no direct texting on open-source platforms, making them invulnerable to cybersecurity breaches. The SekurMail / SekurMessenger, SekurVoice, SekurProVideo Conference, and other products are available now or soon. Sekur’s “Chat-by-Invite” app is available on iOS and Android; go to Sekur.com to download it. Subscribers get cybersecurity protections not available with open-source programs for reasonable pricing. As an added protection to subscribers, Sekur Private Data, Ltd operates its internet platforms and security businesses under the country of Switzerland’s very tough privacy laws. The on-screen QR code is available during the show to download more info or visit Sekur Private Data, Ltd. – http://www.Sekur.com. The on-screen QR code is available during the show; download or visit Sekur Private Data, Ltd. – http://www.Sekur.com. This interview segment initially aired on May 15, 2022.
New to The Street TV re-airs Mr. Loic Gautier, CEO at Leflair, a Society Pass, Inc. (NASDAQ: SOPA) subsidiary, interview with TV Host Jane King. Loic provides viewers with his history in e-commerce and online retail, how Leflair started and eventually became a wholly-owned subsidiary of Society Pass, Inc. Digital commerce takes money and commitment to succeed, Loic explains the business model at Leflair, an e-commerce platform specializing in fashion, and its growth within Vietnam and SE Asia. During COVID-19 shutdowns, e-commerce sites that sold non-essential goods/services had a tough time, Leflair was able to survive the downtrend during 2020 and, in 2021, merged successfully into Society Pass, Inc., a Nasdaq public Company. The relationship between Leflair and Society is a win-win, giving Society Pass a business vertical and Leflair access to capital and human resource talents. Leflair fits perfectly in Society Pass, Inc.’s objective to continue building the next generation of digital ecosystems and loyalty programs in Southeast and South Asia markets. The on-screen QR code is available during the show; download or visit Leflair – https://leflair.com/en/ and Society Pass, Inc. – https://thesocietypass.com/. This interview segment initially aired on June 5, 2022.
The New to The Street TV re-airs on this week show the interview with Mr. Mark Middleton, National Sales Director at PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW) and TV Host Jane King. PetVivo Holdings, Inc. is a biomedical device company that manufactures, commercializes, and licenses innovative medical devices and therapeutics for companion animals. As PETV’s National Sales Director, Mark talks about his history within the pet products industry, dealing with FDA manufacturing, product distributions, capital markets, and mergers/acquisitions. He sees himself as a perfect fit at PETV; he understands the veterinarians (DVMs) needs for best practices and product result outcomes for their clients’ animals. The injectable patented Spryng with OsteoCushion Technology treats osteoarthritis and joint afflictions while providing rehabilitation treatments for horses and dogs and continues to grow as a reliable DVM treatment. Being an entirely naturally derived product, Spryng is superior to competitors’ non-biological, synthetic products, and the Spryng treatment lasts longer. The PETV has a talent team who understands science, finance, sales/marketing, manufacturing, distribution, etc. With patience, persistence, and follow-through, Mark sees a strong future for PETV. The on-screen QR code is available during the show; download or visit PetVivo Holdings, Inc. – https://petvivo.com/ and Spryng with OsteoCushion Technology – https://www.sprynghealth.com/. This interview segment initially aired on June 5, 2022.
New to the Street TV airs its “Weekly Sekur Privacy & Sekur Security Segment” with internationally acclaimed internet privacy expert Mr. Alain Ghiai, CEO at Sekur Private Data Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) and TV Host / Multi-media Journalist Ana Berry. Ana opens the show talking about receiving electronic communication from the Oklahoma State Department of Health on steps to take to prevent being cyber-hacked during vacation travels. The state recommended several suggestions, including checking your device’s settings, installing up-to-date software, and changing passwords. Alain agreed with these suggestions and complimented the State of Oklahoma for being proactive. A common issue is that the factory setting is put back as default when you download a new version of an updated app or software. Alain says these settings are advantageous for the app and software entities harvesting data. After new and updated app downloads, Alain suggests you go into your setting feature and enable all privacy settings, which can eliminate potential spying of your devices. Turn off your location settings on your mobile devices and only use them when necessary for a particular app when needed. An Uber lawsuit awarded damages for unauthorized sharing of location data and developed an industry-wide acceptance of a feature that now notifies end-users of permission-based options. End-users can directly agree or disagree with sharing their data when downloading apps. A password generation program is good to use. Alain, however, recommends using a sentence as your password with upper- and lower-case letters, numbers, and special characters; 8 or more characters is a must for a password. Update passwords every 90-days is a good idea to further protect from a possible hack. Alain suggests not using “Free” Wi-Fi at hotels, restaurants, airports, stores, etc., because open portals are prone to hacking data. Sekur Private Data, Ltd, based in Switzerland, uses its Helix military-grade encryption platform to develop many Sekur products that provide secure and private electronic communications. Emails, text messages, and domain migration are available as subscription-based services. SekurVPN (Virtual Private Network), a new product available soon, gives a single location VPN in Switzerland. Competitor products offer different VPN links based on your location. Having multiple VPNs switching back and forth from place to place can be a possible cybersecurity problem. Hosted in Switzerland, the SekurVPN network is available no matter where you connect. Alain recommends viewers learn more about Sekur products by going to the video tutorials on the Company’s website – https://sekur.com/en/tutorials. For over 1-year now, the “Weekly Sekur Privacy & Sekur Security Segment” provides excellent tips and education on preventing businesses and individuals with potential cybersecurity threats and hacks. Each week, the segment continues forward, and viewers can proactively learn more ways to avoid data breaches. The on-screen QR code is available during the show; download or visit Sekur Private Data, Ltd. – http://www.Sekur.com. “What is your privacy worth?”
Re-airing is the in-person Nasdaq Marketplace studio interviews with Mr. Joe Endoso, Chief Operating Officer (COO), and Ms. Susan Miller, Chief Growth Officer (CGO) at Linqto. They talk with New to The Street’s TV Host Jane King about Linqto helping its client identify, evaluate, and invest in the world’s leading Unicorns. In business, a Unicorn is a privately held startup company valued at over US$1 billion. Joe Endoso explains Linqto’s business platform, founded on the idea of getting individual investors the opportunity to invest in private help tech companies. Some of the enormous investment returns are on the IPOs of tech companies, and Linqto focuses on these private investments before becoming public. It is difficult for individual investors to invest in privately held tech companies, primarily institutions, and the wealthy have the advantages in these private investment vehicles. Joe states that any “Accredited Investor,“ per US SEC definition, can become a Linqto client and invest in privately-held tech companies. He recommends that investors use a percentage of their investment dollars in a private investment strategy. Susan Miller, CGO, talks further about the accredited status, and anyone can go to the portal on the Linqto site to determine accredited eligibility. New rules are pending approval at the US Congressional level, amending the “JOBS ACT,” which might lower the threshold requirements for individuals to participate in private investments. Generational wealth occurs more often with private investments in high-tech entities before IPOs. Linqto is private investing made simple; sign-up now. The on-screen QR code is available during the show; download or visit Linqto – https://www.linqto.com/. This interview segment initially aired on June 5, 2022.
About Tonix Pharmaceuticals Holding Corp. (TNXP):
Tonix Pharmaceuticals Holding Corp. (TNXP) is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring, and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio comprises immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer. TNX-15001 is a humanized monoclonal antibody targeting CD40-ligand in development to prevent the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the second half of 2022. Tonix’s rare disease portfolio includes TNX-29002 for the treatment of Prader-Willi syndrome. The FDA has granted TNX-2900 Orphan-Drug Designation. Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox called TNX-8013, next-generation vaccines to prevent COVID-19, and an antiviral to treat COVID-19. Tonix’s lead vaccine candidates for COVID-19 are TNX-1840 and TNX-18504, live virus vaccines based on Tonix’s recombinant pox vaccine (RPV) platform. TNX-35005 (sangivamycin, i.v. solution) is a small molecule antiviral drug to treat acute COVID-19 and is in the pre-IND stage of development. TNX-102 SL, (cyclobenzaprine HCl sublingual tablets) is a small molecule drug being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the second quarter of 2022. The Company’s CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL, is in mid-Phase 3 development to manage fibromyalgia, with a new Phase 3 study launched in the second quarter of 2022. Finally, TNX-13006 is a biologic designed to treat cocaine intoxication that is expected to start a Phase 2 trial in the second quarter of 2022 – https://www.tonixpharma.com. (1TNX-1500 is an investigational new biologic at the pre-IND stage of development and has not been approved for any indication.2TNX-2900 is an investigational new drug at the pre-IND stage of development and has not been approved for any indication.3TNX-801 is a live horsepox virus vaccine for percutaneous administration in development to protect against smallpox and monkeypox. TNX-801 is an investigational new biologic and has not been approved for any indication.4TNX-1840 and TNX-1850 are live horsepox virus vaccines for percutaneous administration, in development to protect against COVID-19. TNX-1840 and TNX-1850 are designed to express the SARS-CoV-2 spike protein from the omicron and BA.2 variants, respectively. TNX-1840 and TNX-1850 are investigational new biologics at the pre-IND stage of development and have not been approved for any indication. 5TNX-3500 is an investigational new drug at the pre-IND stage of development and has not been approved for any indication.6TNX-1300 is an investigational new biologic and has not been approved for any indication.)
About Sekur Private Data Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0):
Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) is a Cybersecurity and Internet privacy provider of Swiss hosted solutions for secure communications and secure data management. The Company distributes encrypted emails, secure messengers, secure communication tools, secure cloud-based storage, disaster recovery, and document management products. The Company sells and serves consumers, businesses, and governments worldwide through approved wholesalers, distributors, and telecommunications companies. Contact Sekur Private Data, Ltd. at email@example.com or visit https://www.sekurprivatedata.com and https://www.sekur.com.
Leflair, based in Ho Chi Minh City, Vietnam, is an online premium outlet for Fashion, Beauty, and Home Furnishing products. In December 2015, Leflair sold over 2,500 brands via its flash-sales model. Society Pass, Inc. (NASDAQ: SOPA) acquired Leflair’s assets in February 2021 and relaunched Leflair back onto the Vietnam market in September 2021. SOPA operates Leflair.com, Vietnam’s leading lifestyle e-commerce platform. Society Pass, Inc. is building the next-generation loyalty and data-focused marketing platform in Southeast Asia and South Asia. The Company’s technology ecosystem enables companies to work synergistically, transforming how consumers and merchants interact. It is all about generating customer loyalty and revenue for merchants and ease of consumer transactions. More transaction data becomes available as more merchants and consumers register on the platform. More data generation creates opportunities to develop loyalty programs – https://thesocietypass.com/ & https://leflair.com/en/.
About PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW):
PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW) is an emerging biomedical device company currently focused on manufacturing, commercializing, and licensing innovative medical devices and therapeutics for companion animals. The Company’s strategy is to leverage human therapies to treat companion animals time-efficiently and less costly. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices that enter the market much earlier than more stringently regulated pharmaceuticals and biologics. PetVivo has a pipeline of seventeen products to treat animals and people. A portfolio of nineteen patents protects the Company’s biomaterials, products, production processes, and use methods. The Company’s lead product Spryng with OsteoCushion Technology, a veterinarian-administered, intraarticular injection to treat lameness and other joint-related affliction, including osteoarthritis, in dogs and horses, is currently available for commercial sale to veterinarians – https://petvivo.com/ & https://www.sprynghealth.com/.
Linqto is enabling a new class of investors to access pre-IPO opportunities. Linqto makes the private securities asset class accessible while reducing costs and saving time with the flexibility of trading directly on its platform. Linqto is easy to use, and its expert team is always available to answer your questions. Private investing made simple – https://www.linqto.com/.
About FMW Media:
FMW Media operates one of the longest-running US and International sponsored and Syndicated Nielsen Rated programming TV brands, “New to The Street” and its blockchain show “Exploring The Block.” Since 2009, these brands have run biographical interview segment shows across major U.S. Television networks. The TV platforms can potentially reach over 540 million homes in the US and international markets. FMW’s New to The Street / Newsmax TV broadcasting platform airs its syndication on Sundays at 10 -11 AM ET. FMW is also one of the nation’s largest buyers of linear television long and short-form – https://www.newsmaxtv.com/Shows/New-to-the-Street & https://www.newtothestreet.com/.
Forward-Looking Statements Disclaimer:
This press release contains forward-looking statements within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of these terms or other comparable terminology. However, not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at which such performance or results are achieved. This press release should be considered in all filings of the Companies contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov.
FMW Media Contact:
+1 (631) 766-7462
“New to The Street” Business Development Office